HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $40 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Annovis Bio (NYSE:ANVS) and maintained a $40 price target.
June 28, 2023 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Annovis Bio and maintained a $40 price target.
The reiteration of a 'Buy' rating and maintenance of a $40 price target by HC Wainwright & Co. indicates a positive outlook for Annovis Bio. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100